Ethylbromazolam Review Recommends Class C Control Under Misuse of Drugs Act 1971
Summary
The Advisory Council on the Misuse of Drugs published a review on 14 April 2026 recommending that the novel benzodiazepine ethylbromazolam be made a Class C drug under the Misuse of Drugs Act 1971 and added to Schedule 1 of the Misuse of Drugs Regulations 2001. The recommendation is based on evidence of misuse and harms associated with the substance.
What changed
The ACMD published a review recommending that ethylbromazolam, a novel benzodiazepine, be controlled as a Class C drug under the Misuse of Drugs Act 1971 and placed in Schedule 1 of the Misuse of Drugs Regulations 2001. This would impose restrictions on possession, supply, manufacture, and importation of the substance.
Pharmaceutical manufacturers, importers, exporters, and healthcare providers who handle ethylbromazolam should monitor for subsequent Home Office action to implement this recommendation. If enacted, entities would face compliance obligations under the controlled substances framework.
What to do next
- Monitor for legislative developments implementing the ACMD recommendation
- Review current handling of ethylbromazolam if applicable
- Consult legal counsel regarding potential scheduling implications
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Research and analysis
Ethylbromazolam: review of the evidence on its use and harms
The report reviews the evidence on the use and harms of the novel benzodiazepine ethylbromazolam and recommends control under the Misuse of Drugs Act 1971.
From: Advisory Council on the Misuse of Drugs Published 14 April 2026 Get emails about this page
Documents
Ethylbromazolam: a review of the evidence on its use and harms (accessible version)
HTML
Ethylbromazolam: a review of the evidence on its use and harms
PDF, 378 KB, 20 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Cover letter from ACMD report on ethylbromazolam (accessible version)
HTML
Cover letter from ACMD report on ethylbromazolam
PDF, 140 KB, 2 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
Based on the review of the currently available evidence, the Advisory Council on the Misuse of Drugs (ACMD) recommends:
- making ethylbromazolam a Class C drug
- adding ethylbromazolam to Schedule 1 of the Misuse of Drugs Regulations 2001
Published 14 April 2026 Get emails about this page Print this page
Named provisions
Related changes
Get daily alerts for Uk Advisory Council On The Misuse Of Drugs
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from ACMD.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Uk Advisory Council On The Misuse Of Drugs publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.